Vanguard Capital Management
TPST icon

Vanguard Capital Management’s Tempest Therapeutics TPST Stock Holding History

Vanguard Capital Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$260K Hold
233,888
– – ﹤0.01% 3797
2026
Q1 		$384K Buy
+233,888
New +$564K ﹤0.01% 3715

Other funds holding TPST

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Vanguard Capital Management's TPST Position: Q2 2026 in Review

Vanguard Capital Management held its Tempest Therapeutics (TPST) position steady in Q2 2026 at 233,888 shares worth $260K. The position accounts for ﹤0.01% of the portfolio, ranked #3797.

Vanguard Capital Management first reported a position in TPST in Q1 2026 and has held it in 2 quarters since. The position peaked at $384K in Q1 2026. 21 funds tracked by Wall St. Rank hold TPST as of Q2 2026.

  • Vanguard Capital Management held 233,888 shares of Tempest Therapeutics worth $260K as of Q2 2026.
  • Vanguard Capital Management left its Tempest Therapeutics share count unchanged in Q2 2026.
  • Tempest Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3797 holding.
  • Vanguard Capital Management first reported a position in Tempest Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Tempest Therapeutics position peaked at $384K in Q1 2026.
  • 21 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.